The January 31 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
While not the most exciting companies in the world, these five Dividend Aristocrats will certainly hold up much better than others should the market take a deep dive.
The top analyst upgrades, downgrades and other research calls from Monday include AbbVie, Apple, Exact Sciences, Freeport-McMoran, Laboratory Corp and Splunk.
Friday was a positive day for the U.S. markets. We are currently in the midst of the fourth quarter earnings season and so far it has been very positive for the markets,…
AbbVie reported better-than-expected fourth-quarter financial results before the markets opened on Friday.
Chris Lange The January 12 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
With the market trading at very extended valuations, and the S&P 500 on the longest streak ever without a 5% correction, it may make sense to move to some safer higher ground.
24/7 Wall St. has put together a preview of Netflix, Ford, AbbVie and other top companies reporting their latest quarterly results in the coming week.
The December 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Credit Suisse has put together a list of biopharma companies in its coverage universe that stand to make significant moves in 2018.
The top analyst upgrades, downgrades and other research calls from Thursday include Alphabet, Avon, Bank of America, Intel, Roku, Snap and Western Digital.
Is it finally time to consider the old adage that "nothing lasts forever" for the bull market as we enter 2018? Here are 10 things that could wreck the current bull market…
The December 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks increased.
The November 30 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks was mixed.
It is no secret that biotech stocks can bring great rewards for investors. They can also deliver serious pain. Fortunately, most of these are currently projected to deliver a solid 2018.
